STAT+: Pharmalittle: We’re reading about an FDA commissioner candidate, Germany’s plans for drug prices, and more

Heidi Overton, a White House policy aide, is reportedly among the final candidates being considered by the Trump administration to lead the U.S. Food and Drug Administration (FDA). Bloomberg News reported that no final decision has been made, and it remains unclear if Overton has the backing of U.S. Health and Human Services Secretary Robert F. Kennedy Jr. Overton, who holds a medical doctorate and a doctorate in clinical investigation from Johns Hopkins University, currently serves as a deputy assistant to the president for domestic policy, focusing on health issues. She previously worked at the America First Policy Institute and was a White House fellow during the first Trump administration.

Eli Lilly anticipates launching its weight loss pill in Europe and the U.K. during the latter half of 2026 or early 2027. Reuters reported that the drugmaker intends to target the out-of-pocket telehealth market, mirroring its strategy in the United States. While Eli Lilly plans to seek public reimbursement from European governments where feasible, new U.S. drug pricing policies are creating complexities in negotiations with health authorities. The company's approach will align with its understanding of the Trump administration's "most-favored nation" framework, which ties drug prices to adjusted U.S. net prices for other countries.